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N-methyl-2-pyridone-5-carboxamide: A novel uremic toxin? fact does not raise a great interest in the physiologic
Background. N-methyl-2-pyridone-5-carboxamide (2PY) is conditions because serum 2PY concentration in healthy
one of the end products of nicotinamide-adenine dinucleotide population is very low. However, in renal insufficiency(NAD) degradation. We recently found that serum 2PY con-
the urine excretion of 2PY seems to be significantly re-centrations in chronic renal failure (CRF) patients were en-
duced [2]. Its concentration in serum of uremic patientshanced to the values, which are potentially toxic. The aim of
this study was to determine whether 2PY is an inhibitor of elevates to potentially toxic levels [2].
poly(ADP-ribose) polymerase, the nuclear enzyme that is
highly involved in variety of physiologic events, including regu-
lation of DNA replication and DNA repair. INTRACELLULAR DEGRADATION
Methods. High-performance liquid chromatography (HPLC) OF NAD AND THE ROLE OF
was used to determine 2PY and other NAD catabolite concen-
POLY(ADP-RIBOSE) POLYMERASEtrations in serum of: nondialyzed patients; patients chronically
hemodialyzed; patients after kidney transplantation; and healthy It seems that poly(ADP-ribose) polymerase (PARP-1;
individuals (control group). Moreover, the effect of nicotinamide EC 2.4.2.30) [5] plays an important role in NAD degrada-
and 2PY on poly(ADP-ribose) polymerase (PARP-1) in vitro tion. PARP-1 is a nuclear enzyme, highly involved in awas studied.
variety of extremely important physiologic events, in-Results. The serum nicotinamide, 2PY, and 4PY (N-methyl-
4-pyridone-3-carboxamide) concentrations are many times ele- cluding regulation of gene expression, cellular differenti-
vated in nondialyzed CRF patients when compared with con- ation, apoptosis, DNA replication, and DNA repair [6].
trols. The direct correlations were found between serum 2PY It has been reported that DNA damage enhances the(as well as 4PY and nicotinamide) concentrations and serum
PARP-1 activity many times [5, 7]. This leads to a rapidcreatinine concentration, and negative correlations between
intracellular NAD depletion [5] and, in consequence, toserum concentrations of these compounds and creatinine clear-
ance. The concentration of 2PY decreases considerably after an accumulation of nicotinamide. Nicotinamide may be
hemodialysis (HD) session, but elevates back 48 hours later. reconverted to NAD and/or metabolized to 2PY and
It permanently declines after kidney transplantation. Nicotin- 4PY (N-methyl-4-pyridone-3-carboxamide). All of theseamide and 2PY significantly inhibit PARP-1 activity in vitro.
compounds can be found in healthy human urine, indi-Conclusions. Increased serum 2PY concentration, along
with a deterioration of kidney function and its toxic properties cating an effective excretion of NAD catabolites by the
(significant inhibition of PARP-1 by 2PY), suggest that it could kidney [3]. The pathway for NAD catabolite formation
be a novel uremic toxin. and the role of poly(ADP-ribose) polymerase in NAD
degradation is presented in Fig. 1.
The progressive decrease of the glomerular filtration
rate (GFR) observed in chronic renal disease results in a 2PY AND OTHER NAD CATABOLITES IN
serum accumulation of different compounds with potent CHRONIC RENAL INSUFFICIENCY
biologic and/or toxic actions called uremic toxins [1]. The mean serum 2PY concentration in healthy sub-
Recently, we reported a considerably enhanced serum con- jects is very low, but it increases approximately 20-fold
centration of N-methyl-2-pyridone-5-carboxamide (2PY) (0.83 0.18 vs.15.5 5.8 mol/L; P 0.001) in patients
in patients with CRF [2]. 2PY is one of the end products with advanced renal failure (Fig. 2). The data regression
of nicotinamide-adenine dinucleotide (NAD) degrada- analysis revealed a positive correlation between serum
tion (Fig. 1) [3, 4]. The products of NAD degradation 2PY concentration and serum creatinine concentration
have been detected in urine for more than 50 years. This (r  0.769; P  0.001), and a negative correlation be-
tween serum 2PY concentration and creatinine clearance
Key words: 2PY, uremic toxin, PARP. (r0.708; P 0.001). A considerably enhanced serum
2PY concentration found in patients on maintenance HD 2003 by the International Society of Nephrology
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Fig. 1. The pathway of nicotinamide-adenine
dinucleotide (NAD) degradation.
The serum nicotinamide concentration, a precursor of
2PY, is also considerably increased in uremic patients
(0.026 0.010 vs. 0.29 0.24mol/L; P 0.001). Similar
to 2PY, it directly correlates with serum creatinine con-
centration (r  0.729; P  0.001) and negatively corre-
lates with creatinine clearance (r  0.642; P  0.001).
These data confirm the thesis that the serum accumula-
tion of nicotinamide is due to the inability of the kidney
to clear the circulating compound.
Like 2PY, the serum 4PY concentration (the other
end product of NAD degradation) is very low in healthy
subjects, but it increases approximately 10-fold in pa-
tients with renal insufficiency (0.26  0.09 vs. 2.1  2.6
mol/L; P  0.001). Its direct correlation with serumFig. 2. The serum 2PY concentration in patients with different severi-
ties of renal insufficiency. The effect of hemodialysis (4 hour sessions; creatinine concentration (r  0.794; P  0.001) and its
polysulphone membrane) and kidney transplantation. Control, control negative correlation with creatinine clearance (r0.661;
group (N  19); CRF, groups (N  10) of nondialyzed patients with
P 0.001) indicate the role of renal function impairmentCRF and serum creatinine concentration; CRF1, 210.3  98.5; CRF2,
540.1  68.2; CRF3, 827.6  145.7; HD, group (N  11) of patients as a main reason of serum 4PY accumulation.
on hemodialysis treatment with serum creatinine concentration; HD1 The above data confirm the thesis that the serum accu-
(before HD), 733.6  128.8; HD2 (after HD), 324.2  73.4; HD3 (48
mulation of nicotinamide and its metabolites is due to thehours after HD), 707  112.1; TN, group (N  12) of patients after
kidney transplantation with serum creatinine concentration: 111.3  inability of the kidney to clear the circulating compound.
20.1. Serum creatinine concentration expressed in mol/L. Statistical However, nicotinamide may also be taken with food oranalysis shows CRF1 vs. control; P 0.001; CRF2 vs. CRF1; P 0.005;
produced in the reaction catalyzed by PARP-1. Its intakeCRF3 vs. CRF2; P 0.05; HD1 vs. CRF3; NS; HD2 vs. HD1, and HD3
vs. HD2; P  0.001; TN vs. control; P  0.01. with food appears to be of marginal meaning, since in
control subjects, despite a different kind and a different
amount of food taken, in the serum NAD catabolite
(2PY, 4PY, nicotinamide), concentrations did not fluc-treatment transiently drops right after a dialysis session
tuate significantly. A thesis about an increased produc-(19.3  6.4 vs.10.2  3.4 mol/L; P  0.001), but 48
tion of nicotinamide (and consequently 2PY and 4PYhours later it increases to the initial values (Fig. 2). It
production) has to be taken into consideration, since itappears that successful kidney transplantation is the only
was documented that an oxidative stress (leading to themethod that reduces the serum 2PY concentration per-
DNA breaks) is a natural part of uremia [8, 9]. Thus, wemanently to the values observed in healthy population
might speculate that a PARP-1 activity, a nicotinamide(Fig. 2). All of these data let us suppose that a high
formation, and, by consequence, a production of 2PYserum 2PY concentration found in CRF patients is a
result of kidney function impairment. and 4PY, were enhanced in uremia (see Fig. 1).
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CRF patients and a serum accumulation of these com-
pounds—similar to adenine [13]—increases along with a
deterioration of kidney function. We have also presented
evidence that 2PY has potent PARP-1 inhibitory proper-
ties (it is likely that 4PY also belongs to the PARP-1
inhibitors). This finding is of special relevance since
PARP-1 plays a crucial role in cytoprotective events. We
state that 2PY could be a uremic toxin. It complies with
all the necessary criteria for such a substance. It is likely
that NAD degradation products compose the family of
compounds with features characteristic for uremic toxins.
Fig. 3. The effect of increasing concentrations of nicotinamide and
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